An interventional study of Olmesartan in Type 2 Diabetes Mellitus, Diabetic Kidney Disease and Albuminuria, sponsored by Tri-Service General Hospital (TSGH). Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Tri-Service General Hospital (TSGH) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing olmesartan in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. olmesartan · Diabetes Mellitus, Type 2.
Among the 10 studies testing olmesartan in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is the only one that started in 2022, is the only one with no phase, and was the 10th registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 10 studies testing olmesartan in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Baylor Research Institute · Sites in United States
Ages 18–84
By country, each count listing its studies:
olmesartan: first FDA approval 2002 (BENICAR). What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 254 across the 10 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 8 most frequent:
Tri-Service General Hospital (TSGH) is the lead sponsor of 39 studies on the registry; 12 are open to participants now.
Tri-Service General Hospital (TSGH) has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing olmesartan in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the efficacy and safety of adding olmesartan to sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapy in patients with type 2 diabetes mellitus and persistent albuminuria. Participants receive olmesartan at a dose of either 20 mg or 40 mg daily in addition to their ongoing SGLT2i treatment. Changes in urinary albumin-to-creatinine ratio (UACR), renal function, and blood pressure are assessed over a 9-month follow-up period. The study aims to evaluate the potential additional renoprotective effects of olmesartan in patients with type 2 diabetes who continue to have albuminuria despite SGLT2i therapy.
Diabetic kidney disease is a major complication of type 2 diabetes mellitus. Although sodium-glucose cotransporter-2 inhibitors (SGLT2i) provide established cardiorenal protection, residual albuminuria may persist in some patients despite ongoing treatment.
Olmesartan, an angiotensin II receptor blocker (ARB), reduces intraglomerular pressure and albuminuria through inhibition of the renin-angiotensin system.
This single-center, open-label pilot study evaluates the effects of adding olmesartan at 20 mg or 40 mg daily to ongoing SGLT2i therapy in patients with type 2 diabetes and albuminuria. Renal parameters, including urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and serum creatinine, as well as blood pressure and safety parameters, are assessed during a 9-month follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults with type 2 diabetes mellitus. Patients receiving ongoing sodium-glucose cotransporter-2 inhibitor therapy. Patients with persistent albuminuria who meet the study-defined eligibility criteria.
Patients who are willing and able to provide written .
Exclusion Criteria:
Known or history of severe adverse reactions to other angiotensin receptor blockers (ARBs).
Active liver disease or severe hepatic impairment ( [AST] > 3 × [upper limit of normal]; Alanine transaminase [ALT] > 3 × ULN).
Moderate-to-severe renal impairment (estimated \< 30 mL/min/1.73 m²). Women who are pregnant or currently breastfeeding. Judged by the study investigator to be unsuitable for participating (or continuing) in this trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive olmesartan 20 mg orally once daily in addition to their ongoing SGLT2 inhibitor therapy.
Drug: Olmesartan
Description: Participants receive olmesartan 40 mg orally once daily in addition to their ongoing SGLT2 inhibitor therapy.
Drug: Olmesartan
Olmesartan is administered orally once daily at a dose of 20 mg or 40 mg, according to the assigned study group, as add-on therapy to ongoing sodium-glucose cotransporter-2 inhibitor treatment. Treatment is continued during the 9-month study period.
Percentage Change in Urinary Albumin-to-Creatinine Ratio (UACR) from Baseline to Month 9
The percentage change in urinary albumin-to-creatinine ratio (UACR) from baseline to 9 months after initiation of olmesartan treatment. UACR is measured using urine albumin and creatinine concentrations.
Time frame: Baseline to Month 9
the dose-comparison outcome was a ≥30% UACR reduction at 9 months.
the dose-comparison outcome was a ≥30% UACR reduction at 9 months.
Time frame: Baseline to Month 9
Plan to share: No — The datasets generated and/or analyzed during the current study are not publicly available due to patient privacy and ethical restrictions imposed by the Institutional Review Board of Tri-Service General Hospital. However, de-identified data are available from the corresponding author upon reasonable request and with prior approval from the ethics committee.
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Dec 2023, 14 months.
Of 2,070 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 14 months is below that.
Counting every sponsor, half of 2,247 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olmesartan
Tri-Service General Hospital (TSGH)